The ophthalmologic drug developer has gone public three years after being founded by WuXi AppTec-backed 6 Dimensions Capital.

Pfizer Ventures, billed as an existing investor, contributed to the $72.5m close of the antibody-drug conjugate developer's latest round.

The ultrasound system developer's Edwards Lifesciences-backed series B round will fund product development and commercial growth.

Gilead Sciences returned for a $46.7m round that will support further development of its biosensor-based diagnostics device.

University of Toronto and McMaster University-founded glioblastoma Car T-cell therapy developer Empirca Therapeutics has been acquired by Century Therapeutics.

University of Birmingham's cancer immunotherapy developer Revitope Oncology secured equity funding as part of a $160m alliance with Junshi Biosciences.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Nan Fung Life Sciences and affiliate Pivotal BioVenture Partners invested in the ophthalmology therapy developer having incubated it last year.

New investor Lilly Asia Ventures helped the cancer testing kit provider increase its overall funding to more than $160m.

Marie-Laure Mahé is heading up the recently launched corporate venture capital subsidiary of health and hygeine product maker Essity.